Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 89, Issue 6, Pages 911-914Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2010.355
Keywords
-
Categories
Funding
- Canadian Institute of Health Research
Ask authors/readers for more resources
Isoniazid (INH)-induced hepatotoxicity remains a significant clinical problem, and the current mechanistic hypothesis is incomplete; it is simply referred to as metabolic idiosyncrasy, 1 which is believed to involve cytotoxicity caused by bioactivation of acetylhydrazine, 2 a metabolite of INH. However, this hypothesis is based on animal studies, involving characteristics that are very different from those that pertain to hepatotoxicity in humans, such as delayed onset. This issue therefore deserves a fresh look.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available